Roche Gains FDA Priority Review for Enspryng sBLA in MOGAD with Decision Due January 2027

With no approved disease-modifying therapy currently available for myelin oligodendrocyte glycoprotein antibody-associated disease, Roche's supplemental Biologics License Application for Enspryng (satralizumab) now carries FDA Priority Review status, placing a regulatory decision date of 10 January 2027 on the calendar for biologics manufacturers and sBLA teams tracking rare CNS indications.

The filing acceptance rests on Phase III METEOROID study data, which met its primary endpoint of time to first MOGAD relapse during the double-blind treatment period. Enspryng reduced relapse risk by 68% versus placebo (p=0.0025), with 87% of treated patients remaining relapse-free at 48 weeks compared to 67% in the placebo arm. Secondary endpoints, annualised relapse rate, MRI lesion activity, and rescue therapy use, also showed statistically significant improvement. The safety profile was consistent with over a decade of clinical trial and post-approval experience in neuromyelitis optica spectrum disorder (NMOSD).

For regulatory affairs leads, the sBLA pathway here is instructive. Enspryng already holds approval in approximately 90 countries for NMOSD as the first IL-6 inhibitor in that indication, giving Roche an established post-market safety dataset exceeding 10,000 patients. That prior approval history, combined with orphan drug designation in both the U.S. and E.U. for MOGAD, materially shapes the evidentiary standard and review timeline for this supplemental filing. This is also Enspryng's second FDA Priority Review in 2026, following one granted for thyroid eye disease in June.

The European Medicines Agency has separately validated a MOGAD application, with a European Commission decision anticipated in the third quarter of 2027. QA and regulatory leads at biologics sites supporting Roche's supply chain should note the divergent timelines: a potential U.S. launch readiness window opens in early 2027, while EU commercial activation follows roughly six months later.

Enspryng, developed by Chugai within the Roche Group, uses recycling antibody technology designed to enable repeated IL-6 receptor binding and sustained suppression of inflammatory pathways, a mechanism Roche is also pursuing in autoimmune encephalitis and thyroid eye disease.

The 10 January 2027 PDUFA date sets the immediate operational checkpoint for manufacturing scale readiness, labelling updates, and any pre-approval inspection activity that FDA may schedule against Roche's biologics facilities.

Source: Roche via GlobeNewswire, 10 September 2026.